COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.

Amy C ShermanJessica TuanValeria D CantosOladunni AdeyigaScott MahoneyAna M Ortega-VillaAmy TillmanJennifer WhitakerAmanda S Woodward DavisBrett LeavIan HirschJerald SadoffLisa M DunklePeter B GilbertHolly E JanesJames G KublinPaul A GoepfertKaren KotloffNadine RouphaelAnn R FalseyHana M El SahlyMagdalena E SobieszczykYunda HuangKathleen M NeuzilLawrence CoreyBeatriz GrinsztejnGlenda GrayMartha NasonLindsey R BadenCynthia L Gay

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)

For individuals with mildly immunocompromising conditions, there is no evidence of differences in VE against symptomatic or severe COVID-19 compared with those with non-TIS in the 4 COVID-19 vaccine randomized controlled efficacy trials.

Keyphrases

coronavirus disease
sars cov
randomized controlled trial
respiratory syndrome coronavirus
open label
early onset
systematic review
clinical trial
study protocol
phase ii